Published in
Oxford University Press (OUP), Clinical Infectious Diseases, 11(63), p. 1479-1481
DOI: 10.1093/cid/ciw579
Links
Tools
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Journal article published in 2016 by
Jason Grebely,
Gj Dore,
Stefan Zeuzem,
Rj Aspinall,
Raymond Fox,
Lingling Han,
John McNally,
Anu Osinusi,
Dm Brainard,
Gm Mani Subramanian,
Macky Natha,
Gr Foster 
,
Alessandra Mangia,
Mark Sulkowski,
Jordan Jj Feld
,
Alessandra Mangia,
Mark Sulkowski,
Jordan Jj Feld
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.